Asset Details
Do you wish to reserve the book?
The efficacy of extracorporeal photopheresis in the treatment of steroid refractory acute graft-versus-host disease: a systematic review and meta-analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The efficacy of extracorporeal photopheresis in the treatment of steroid refractory acute graft-versus-host disease: a systematic review and meta-analysis
Do you wish to request the book?
The efficacy of extracorporeal photopheresis in the treatment of steroid refractory acute graft-versus-host disease: a systematic review and meta-analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The efficacy of extracorporeal photopheresis in the treatment of steroid refractory acute graft-versus-host disease: a systematic review and meta-analysis
2025
Overview
Steroid-refractory acute graft-versus-host disease (SR-aGVHD) is a significant complication of hematopoietic stem cell transplantation (HSCT). Extracorporeal Photopheresis (ECP) represents a key second-line option. Previous reviews have provided valuable insights, and recent studies allow for an updated synthesis of efficacy, safety, and patterns of ECP use in SR-aGVHD, including outcomes not fully analysed previously. This study aims to address the literature gap by providing a comprehensive updated review of the efficacy of ECP and its patterns of use in SR-aGVHD.
A Systematic literature search was conducted as per PRISMA guidelines, up to September 2024, using the PubMed, Scopus, and Cochrane databases. Studies investigating the use of ECP in the setting of chronic GVHD, GVHD prophylaxis, or first-line treatment of aGVHD were excluded. Meta-analyses using fixed and random effects models were employed to estimate the pooled effect sizes.
Thirty-eight studies, including a total of 1249 participants, were included, and 29 were included in the quantitative analyses. Most studies focused on the adult population, and the majority used a retrospective single-arm study design (n = 30). Overall, skin, gut, and liver response rates were 72%, 89%, 54%, and 36%, respectively. The pooled steroid-sparing percentage was 66%. ECP showed significantly higher survival in patients with grade 2 GVHD compared with grades 3 and 4 (HR: 2.35, 95% CI: 1.67 - 3.29). ECP demonstrated a positive trend in overall survival compared to other treatments, but the results were not significant.
This review indicates that ECP is an effective treatment for SR-aGVHD, with favorable response and survival outcomes. However, due to the heterogeneity observed in the analyses among the studies, more controlled trials are needed to establish its effects in combination with other agents and against other regimens.
https://www.crd.york.ac.uk/prospero/, identifier CRD42024585471.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ acute graft-versus-host disease (aGVHD)
/ Bias
/ extracorporeal photopheresis (ECP)
/ Graft vs Host Disease - etiology
/ Graft vs Host Disease - mortality
/ Graft vs Host Disease - therapy
/ Hematopoietic Stem Cell Transplantation - adverse effects
/ Humans
/ Patients
/ Photopheresis - adverse effects
/ steroid refractory acute graft-versus-host disease
/ Steroids
